U.S. market Closed. Opens in 3 hours 33 minutes

ABCL | AbCellera Biologics Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 2.9600 - 3.14
52 Week Range 2.3350 - 5.62
Beta 0.51
Implied Volatility 101.15%
IV Rank 56.79%
Day's Volume 3,684,069
Average Volume 2,732,840
Shares Outstanding 295,366,000
Market Cap 903,819,960
Sector Healthcare
Industry Biotechnology
IPO Date 2020-12-11
Valuation
Profitability
Growth
Health
P/E Ratio -5.02
Forward P/E Ratio 18.56
EPS -0.61
1YR Price Target 28.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 586
Country Canada
Website ABCL
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
ABCL's peers: CWBR, HEPA, RAIN, KRYS, AVRO, CVAC, RETA, VIR, PPCB, PTCT, SRPT, IOVA, MDGL, CGC
*Chart delayed
Analyzing fundamentals for ABCL we got that it has weak fundamentals where Valuation is considered to be slightly undervalued, Profitability is unacceptably poor, Growth is very good and Health is weak. For more detailed analysis please see ABCL Fundamentals page.

Watching at ABCL technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on ABCL Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙